🙏🙏Immensely grateful for the generous support and guidance from Dr. Ann Marie Navar, @virani_md, @ericpetersonMD, and @dramitkhera 🙏🙏 And many thanks to @JAMAInternalMed for offering an avenue to share our findings

How does the move to PREVENT for ASCVD risk estimation affect aspirin use❓ 📜jamanetwork.com/journals/jam… 1⃣ >80% eligible for 1ry prevention aspirin based on a PCE risk >10% would no longer be eligible w/ PREVENT 2⃣ Most current aspirin users don't qualify under either calculator

🙏Incredibly grateful to @almallahmo for supervision , @MalekNayfeh, Fares AlAhdab, Mahmoud Al Rifai, @DmitryAbramovMD, @FudimMarat , @YasMoayedi, @RayanYousefzai for their incredible support, and to @JACCJournals CV imaging for the opportunity to publish our work🙏

Do heart transplant patients always need invasive angio to screen for graft vasculopathy❓ 📜authors.elsevier.com/a/1lWfA… In this meta-analysis, CTA/PET had pretty respectable sensitivity/NPV for ruling out graft vasculopathy compared to a gold standard of invasive angiography.

🙏🙏Incredibly thankful to @almallahmo and Dr. Al Rifai for their supervision & guidance on this; and to my brilliant colleague @MariaAlwan_ 🙏🙏 And thank you to @EHJCVIEiC for allowing us to share our findings!

Patients with a normal-ish EF could be further stratified as being at a *truly* low-risk of events or at intermediate risk depending on their rest flow. In contrast, patients with a depressed EF had a uniformly high rate of events regardless.

Our hypothesis was that an elevated amount of myocardial blood flow at rest, which PET can measure, would predict adverse event rates. And it did, esp. in patients with a normal EF at rest.

First, some background. Prior data indicated that the myocardium of patients with LVH/HFpEF receives an excessive amount of blood flow at rest (doi.org/10.1161/CIRCHEARTFAI…) There is also mechanistic data that medications effective in HFpEF reduce this (doi.org/10.2337/db20-0921)